{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:39:11Z","timestamp":1770273551439,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T00:00:00Z","timestamp":1392163200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1752-1947-8-48","type":"journal-article","created":{"date-parts":[[2014,2,12]],"date-time":"2014-02-12T12:04:25Z","timestamp":1392206665000},"source":"Crossref","is-referenced-by-count":6,"title":["Rupture of abdominal aortic aneurysm after intravitreal bevacizumab injection: a case report"],"prefix":"10.1186","volume":"8","author":[{"given":"Sung UK","family":"Baek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon IL","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,2,12]]},"reference":[{"key":"2697_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000323943","volume":"225","author":"AM Carneiro","year":"2011","unstructured":"Carneiro AM, Barthelmes D, Falc\u00e3o MS, Mendon\u00e7a LS, Fonseca SL, Gon\u00e7alves RM, Faria-Correia F, Falc\u00e3o-Reis FM: Arterial thromboembolic events in patients with exudative age-related macular degeneration treated with intravitreal bevacizumab or ranibizumab. Ophthalmologica. 2011, 225: 211-221. 10.1159\/000323943.","journal-title":"Ophthalmologica"},{"key":"2697_CR2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","volume":"246","author":"L Wu","year":"2008","unstructured":"Wu L, Martinez-Castellanos MA, Quiroz-Mercado H: Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefe\u2019s Arch Clin Exp Ophthalmol. 2008, 246: 81-87.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"2697_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1001\/archophthalmol.2010.223","volume":"128","author":"LH Curtis","year":"2010","unstructured":"Curtis LH, Hammill BG, Schulman KA: Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010, 128: 1273-1279. 10.1001\/archophthalmol.2010.223.","journal-title":"Arch Ophthalmol"},{"key":"2697_CR4","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1001\/jama.291.15.1900","volume":"291","author":"NM Bressler","year":"2004","unstructured":"Bressler NM: Age-related macular degeneration is the leading cause of blindness. JAMA. 2004, 291: 1900-1901. 10.1001\/jama.291.15.1900.","journal-title":"JAMA"},{"key":"2697_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1210\/er.2003-0027","volume":"25","author":"N Ferrara","year":"2004","unstructured":"Ferrara N: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004, 25: 581-611. 10.1210\/er.2003-0027.","journal-title":"Endocr Rev"},{"key":"2697_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/00006982-200502000-00001","volume":"25","author":"AP Adamis","year":"2005","unstructured":"Adamis AP, Shima DT: The role of vascular endothelial growth factor in ocular health and disease. Retina. 2005, 25: 111-118. 10.1097\/00006982-200502000-00001.","journal-title":"Retina"},{"key":"2697_CR7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3928\/1542-8877-20050701-14","volume":"36","author":"PJ Rosenfeld","year":"2005","unstructured":"Rosenfeld PJ, Moshfeghi AA, Puliafito CA: Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005, 36: 331-335.","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"2697_CR8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","volume":"113","author":"RL Avery","year":"2006","unstructured":"Avery RL, Pieramici DJ, Rabena MD: Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006, 113: 363-372. 10.1016\/j.ophtha.2005.11.019.","journal-title":"Ophthalmology"},{"key":"2697_CR9","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006, 355: 1419-1431. 10.1056\/NEJMoa054481.","journal-title":"N Engl J Med"},{"key":"2697_CR10","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006, 355: 1432-1444. 10.1056\/NEJMoa062655.","journal-title":"N Engl J Med"},{"key":"2697_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM: Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007, 114: 855-859. 10.1016\/j.ophtha.2007.01.017.","journal-title":"Ophthalmology"},{"key":"2697_CR12","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1097\/IAE.0b013e318158ea28","volume":"27","author":"MW Stewart","year":"2007","unstructured":"Stewart MW: Predicted biologic activity of intravitreal bevacizumab. Retina. 2007, 27: 1196-1200. 10.1097\/IAE.0b013e318158ea28.","journal-title":"Retina"},{"key":"2697_CR13","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S0741-5214(98)70158-2","volume":"28","author":"JS Lindholt","year":"1998","unstructured":"Lindholt JS, Heickendorff L, Antonsen S, Fasting H, Henneberg EW: Natural history of abdominal aortic aneurysm with and without coexisting chronic obstructive pulmonary disease. J Vasc Surg. 1998, 28: 226-233. 10.1016\/S0741-5214(98)70158-2.","journal-title":"J Vasc Surg"},{"key":"2697_CR14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1067\/mva.2000.105665","volume":"32","author":"SJ Palm","year":"2000","unstructured":"Palm SJ, Russwurm GP, Chang D, Rozenblit AM, Ohki T, Veith FJ: Acute enlargement and subsequent rupture of an abdominal aortic aneurysm in a patient receiving chemotherapy for pancreatic carcinoma. J Vasc Surg. 2000, 32: 197-200. 10.1067\/mva.2000.105665.","journal-title":"J Vasc Surg"},{"key":"2697_CR15","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/01.CIR.0000133279.07468.9F","volume":"110","author":"AR Brady","year":"2004","unstructured":"Brady AR, Thompson SG, Fowkes FG, Greenhalgh RM, Powell JT: Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation. 2004, 110: 16-21. 10.1161\/01.CIR.0000133279.07468.9F.","journal-title":"Circulation"},{"key":"2697_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1161\/01.CIR.97.1.99","volume":"97","author":"T Murohara","year":"1998","unstructured":"Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM: Vascular endothelial growth factor\/vascular permeability via nitric oxide and prostacyclin. Circulation. 1998, 97: 99-107. 10.1161\/01.CIR.97.1.99.","journal-title":"Circulation"},{"key":"2697_CR17","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1161\/01.ATV.0000030186.66672.36","volume":"22","author":"BC Kuenen","year":"2002","unstructured":"Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, Pinedo HM, Hoekman K: Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor\/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vas Biol. 2002, 22: 1500-1505. 10.1161\/01.ATV.0000030186.66672.36.","journal-title":"Arterioscler Thromb Vas Biol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-8-48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1752-1947-8-48\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-8-48","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-8-48.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T07:41:30Z","timestamp":1548142890000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/1752-1947-8-48"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,12]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2697"],"URL":"https:\/\/doi.org\/10.1186\/1752-1947-8-48","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,12]]},"article-number":"48"}}